KYORIN Pharmaceutical (4569) Q1 2026 earnings summary

Executive summary

• Net sales for the quarter ended June 30, 2025, rose 6.4% year-over-year to ¥30,229 million.

• Operating profit increased 106.0% year-over-year to ¥2,624 million.

• Profit attributable to owners of parent surged 137.1% year-over-year to ¥2,100 million.

• Comprehensive income for the quarter was ¥2,020 million, up 72.2% year-over-year.

Financial highlights

• Earnings per share (basic) for the quarter was ¥36.57, up from ¥15.42 in the prior year.

• Equity ratio improved to 71.4% as of June 30, 2025, from 70.4% at March 31, 2025.

• Total assets stood at ¥190,569 million, with net assets at ¥136,153 million as of June 30, 2025.

Outlook and guidance

• Full-year net sales forecast at ¥127,000 million, a 2.4% decrease year-over-year.

• Full-year operating profit projected at ¥6,100 million, down 51.5% year-over-year.

• Full-year profit attributable to owners of parent expected at ¥4,800 million, a 47.2% decrease year-over-year.

• Full-year earnings per share forecast at ¥83.55.

• No revisions to dividend forecast; annual dividend expected to remain at ¥57.00 per share.